Clinical Trial

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Protocol Amendment History 30 amendments
This ClinicalTrials.gov record has been amended 30 times since 2021-03-03; most recent amendment 2026-06-26.
Status change: Not Yet Recruiting → Recruiting 2021-03-19
Trial Details
NCT Number NCT04786262
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Enrollment 52 participants
Start Date 2021-03-29
Primary Completion 2027-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-30